MX391378B - Derivados de fluoroalquil-, fluoroalcoxi-, fenoxi-, heteroariloxi-, alcoxi- y amina-1,4-benzoquinona para tratamiento de trastornos de estres oxidativo. - Google Patents

Derivados de fluoroalquil-, fluoroalcoxi-, fenoxi-, heteroariloxi-, alcoxi- y amina-1,4-benzoquinona para tratamiento de trastornos de estres oxidativo.

Info

Publication number
MX391378B
MX391378B MX2018007389A MX2018007389A MX391378B MX 391378 B MX391378 B MX 391378B MX 2018007389 A MX2018007389 A MX 2018007389A MX 2018007389 A MX2018007389 A MX 2018007389A MX 391378 B MX391378 B MX 391378B
Authority
MX
Mexico
Prior art keywords
treatment
oxidative stress
compounds
fluoroalkoxy
heteroaryloxy
Prior art date
Application number
MX2018007389A
Other languages
English (en)
Spanish (es)
Other versions
MX2018007389A (es
Inventor
Andrew W Hinman
Steven J Richards
Original Assignee
Ptc Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ptc Therapeutics Inc filed Critical Ptc Therapeutics Inc
Publication of MX2018007389A publication Critical patent/MX2018007389A/es
Publication of MX391378B publication Critical patent/MX391378B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C225/00—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones
    • C07C225/24—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones the carbon skeleton containing carbon atoms of quinone rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/07—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/02—Sulfones; Sulfoxides having sulfone or sulfoxide groups bound to acyclic carbon atoms
    • C07C317/04—Sulfones; Sulfoxides having sulfone or sulfoxide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C50/00—Quinones
    • C07C50/24—Quinones containing halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C50/00—Quinones
    • C07C50/26—Quinones containing groups having oxygen atoms singly bound to carbon atoms
    • C07C50/28—Quinones containing groups having oxygen atoms singly bound to carbon atoms with monocyclic quinoid structure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/06—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with radicals, containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/65—One oxygen atom attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/10—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms
    • C07D295/104—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/108—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/10—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms
    • C07D295/112—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C07D295/116—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings with the doubly bound oxygen or sulfur atoms directly attached to a carbocyclic ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
MX2018007389A 2015-12-17 2016-12-17 Derivados de fluoroalquil-, fluoroalcoxi-, fenoxi-, heteroariloxi-, alcoxi- y amina-1,4-benzoquinona para tratamiento de trastornos de estres oxidativo. MX391378B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562269016P 2015-12-17 2015-12-17
PCT/US2016/067404 WO2017106803A1 (en) 2015-12-17 2016-12-17 Flouroalkyl, flouroalkoxy, phenoxy, heteroaryloxy, alkoxy, and amine 1,4-benzoquinone derivatives for treatment of oxidative stress disorders

Publications (2)

Publication Number Publication Date
MX2018007389A MX2018007389A (es) 2018-08-15
MX391378B true MX391378B (es) 2025-03-21

Family

ID=57750640

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018007389A MX391378B (es) 2015-12-17 2016-12-17 Derivados de fluoroalquil-, fluoroalcoxi-, fenoxi-, heteroariloxi-, alcoxi- y amina-1,4-benzoquinona para tratamiento de trastornos de estres oxidativo.

Country Status (8)

Country Link
US (3) US10703701B2 (enExample)
EP (1) EP3389646A1 (enExample)
JP (2) JP6905527B2 (enExample)
CN (2) CN108712903A (enExample)
AU (2) AU2016369616B2 (enExample)
CA (1) CA3008849A1 (enExample)
MX (1) MX391378B (enExample)
WO (1) WO2017106803A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2564843B1 (en) 2005-06-01 2018-12-26 Bioelectron Technology Corporation Redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers
DK2220030T3 (en) 2007-11-06 2016-04-11 Edison Pharmaceuticals Inc 4- (P-QUINONYL) -2-HYDROXYBUTANAMIDDERIVATER TO TREAT mitochondrial
MX363223B (es) 2008-09-10 2019-03-15 Bioelectron Tech Corp Tratamiento de trastornos generalizados del desarrollo con terapeuticos con actividad redox.
ES2553557T3 (es) 2008-10-28 2015-12-10 Edison Pharmaceuticals, Inc. Proceso para la producción de alfa-tocotrienol y derivados
JP2014520894A (ja) 2011-07-19 2014-08-25 エジソン ファーマシューティカルズ， インコーポレイテッド 非アルファトコトリエノールの存在下でのアルファトコトリエノールの選択的酸化のための方法
PL3233786T3 (pl) 2014-12-16 2022-06-13 Ptc Therapeutics, Inc. Polimorficzne i amorficzne postacie (r)-2-hydroksy-2-metylo-4-(2,4,5-trimetylo-3,6-dioksocykloheksa-1,4-dienylo)butanoamidu
EP3390377A1 (en) 2015-12-16 2018-10-24 BioElectron Technology Corporation Improved methods for enriching alpha-tocotrienol from mixed tocol compositions
WO2017106803A1 (en) 2015-12-17 2017-06-22 Bioelectron Technology Corporation Flouroalkyl, flouroalkoxy, phenoxy, heteroaryloxy, alkoxy, and amine 1,4-benzoquinone derivatives for treatment of oxidative stress disorders
JP2018083799A (ja) 2016-11-15 2018-05-31 バイオエレクトロン テクノロジー コーポレイション ２−置換アミノ−ナフト［１，２−ｄ］イミダゾール−５−オン化合物またはその製薬学上許容される塩
WO2018191732A1 (en) 2017-04-14 2018-10-18 Bioelectron Technology Corporation Methods and compositions for treatment of inflammation and oxidative stress
BR112021007153A2 (pt) 2018-10-17 2021-07-20 Ptc Therapeutics, Inc. 2,3,5-trimetil-6-nonilcicloexa-2,5-dieno-1,4-diona para a supressão e tratamento de a-sinucleinopatias, tauopatias e outros distúrbios
US11497758B2 (en) 2018-11-15 2022-11-15 Samuel L. Shepherd Method of treating oxidative stress due to radiation exposure
CA3156499A1 (en) 2019-10-04 2021-04-08 Stealth Biotherapeutics Inc. CHINONE, HYDROCHINONE AND NAPHTOCHINONE ANALOGS OF VATIQUINONE FOR THE TREATMENT OF DISEASES WITH MITOCHONDRIAL DISORDERS
WO2021202986A1 (en) * 2020-04-03 2021-10-07 Stealth Biotherapeutics Corp Compositions and methods for the prevention and/or treatment of mitochondrial disease, including friedreich's ataxia
EP4194435A4 (en) * 2020-08-07 2024-09-25 Taiho Pharmaceutical Co., Ltd. Novel cycloalkenone compound or salt thereof
CN113173842B (zh) * 2021-04-18 2023-09-19 广西大学 2-烷基对苯二醌类化合物的合成方法
WO2023283466A1 (en) 2021-07-08 2023-01-12 Ptc Therapeutics, Inc. Pharmaceutical compositions comprising 2,3,5-trimethyl-6-nonylcyclohexa-2,5-diene-1,4-dione
AU2022204064A1 (en) 2021-07-16 2023-02-02 Samuel L. Shepherd Method of treating oxidative stress due to radiation exposure
CN118984818A (zh) * 2022-02-09 2024-11-19 大鹏药品工业株式会社 环己酮化合物的晶型

Family Cites Families (264)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2856414A (en) 1958-10-14 Oxidation of alpha-tocopherol
FR5531E (fr) 1905-03-02 1906-05-02 Gaston Levy Lajeunesse Perfectionnements aux moteurs à explosions
US2398418A (en) 1943-08-27 1946-04-16 Louis F Fieser Introduction of organic radicals into quinones
FR1201200A (fr) 1958-08-08 1959-12-29 Sogespar S A Procédé de fabrication de l'alpha tocophéryl-quinone
US3071512A (en) 1959-01-26 1963-01-01 Sogespar S A New hypotensive pharmaceutical preparation containing alpha-tocopheryl-quinone
US3406188A (en) 1964-03-27 1968-10-15 Sun Oil Co Preparation of alpha-tocopherylquinone
FR1536576A (fr) 1967-08-29 1968-08-16 Eastman Kodak Co Procédés d'enrichissement et de fractionnement de mélanges à base de tocophérols
US3849453A (en) 1970-03-17 1974-11-19 Takeda Chemical Industries Ltd Quinone derivatives
US3705239A (en) 1970-10-16 1972-12-05 Roy B Gregory Pain removing compositions and methods
UST917001I4 (en) 1971-12-02 1973-12-04 Defensive publication
JPS4875564A (enExample) 1972-01-08 1973-10-11
JPS4988862A (enExample) 1972-12-29 1974-08-24
JPS5245698B2 (enExample) 1973-04-06 1977-11-17
US3957836A (en) 1973-07-02 1976-05-18 Takeda Chemical Industries, Ltd. Quinone derivatives
US3909376A (en) 1974-12-04 1975-09-30 Basf Ag Electrolytic manufacture of alkyl-substituted hydroquinones
JPS52111576A (en) 1976-03-15 1977-09-19 Teijin Ltd Synthesis of 5,7,8-trimethyl-3,4-dehydrotocotrienol
JPS5938203B2 (ja) 1976-04-26 1984-09-14 エーザイ株式会社 補酵素ｑを主成分とする脳循環障害治療剤
LU77344A1 (enExample) 1977-05-16 1979-01-19
US4153614A (en) 1978-05-12 1979-05-08 Hoffmann-La Roche Inc. Synthesis of (S)-(+)-6-hydroxy-2,5,7,8-tetramethylchroman-2-methanol and intermediates therein
US4201879A (en) 1977-05-16 1980-05-06 Hoffmann-La Roche Inc. Hydroquinones
US4201726A (en) 1977-05-17 1980-05-06 Hoffmann-La Roche Inc. Synthesis of Vitamin E
US4310465A (en) 1977-05-17 1982-01-12 Hoffmann-La Roche Inc. Synthesis of vitamin E and quinone intermediates
US4243598A (en) 1977-05-17 1981-01-06 Hoffmann-La Roche Inc. Synthesis of vitamin E
US4127608A (en) 1977-05-17 1978-11-28 Hoffmann-La Roche Inc. Synthesis of Vitamin E
US4185154A (en) 1977-05-17 1980-01-22 Hoffmann-La Roche, Inc. Synthesis of vitamin E
JPS5640651A (en) 1979-09-12 1981-04-16 Takeda Chem Ind Ltd Quinone compound and its preparation
JPS56147746A (en) 1980-04-15 1981-11-16 Takeda Chem Ind Ltd Quinones and their preparation
JPS567734A (en) 1979-06-28 1981-01-27 Takeda Chem Ind Ltd Preparation of quinone derivative
JPS567737A (en) 1979-07-02 1981-01-27 Takeda Chem Ind Ltd Physiologically active quinone and its preparation
JPS5697223A (en) 1979-12-30 1981-08-05 Takeda Chem Ind Ltd Tissue metabolism activator
JPH0193554A (ja) 1980-04-07 1989-04-12 Takeda Chem Ind Ltd 有機化合物
JPS56140943A (en) 1980-04-07 1981-11-04 Takeda Chem Ind Ltd Preparation of organic compound
US4393075A (en) 1980-04-14 1983-07-12 Takeda Chemical Industries, Ltd. Quinone compounds and their use in suppressing the production of SRS-A in mammals
JPS5750935A (en) 1980-09-12 1982-03-25 Otsuka Pharmaceut Co Ltd 1,4-benzoquinone derivative
JPS57131735A (en) 1981-02-09 1982-08-14 Takeda Chem Ind Ltd Preparation of quinones
JPS57183782A (en) 1981-04-30 1982-11-12 Sumitomo Chem Co Ltd Preparation of coumarone compound
JPS5818374A (ja) 1981-07-27 1983-02-02 Nitsusui Seiyaku Kk エイコサペンタエン酸トコフエロ−ルエステル
JPS5883698A (ja) 1981-11-13 1983-05-19 Takeda Chem Ind Ltd キノン化合物およびその製造法
JPS58193689A (ja) 1982-05-10 1983-11-11 Shiseido Co Ltd テストステロン−５α−レダクタ−ゼ阻害剤
DK449983A (da) 1982-10-27 1984-04-28 Hoffmann La Roche Fremgangsmaade til fremstilling af optiske aktive forbindelser
CH655005A5 (it) 1983-02-16 1986-03-27 Sigma Tau Ind Farmaceuti Composizione farmaceutica ad azione metabolica ed energetica utilizzabile in terapia cardiaca e vascolare.
JPS59163316A (ja) 1983-03-08 1984-09-14 Eisai Co Ltd けいれんの治療・予防剤
JPS6028919A (ja) 1983-07-28 1985-02-14 Shiseido Co Ltd 皮膚外用剤
EP0134198A1 (de) 1983-08-10 1985-03-13 Ciba-Geigy Ag Verwendung von Chinonderivaten zum Schützen von Kulturpflanzen vor der phytotoxischen Wirkung von Herbiziden
JPS60197621A (ja) 1984-03-19 1985-10-07 Hohnen Oil Co Ltd コレステロ−ル低下剤
US5304658A (en) 1984-08-01 1994-04-19 Takeda Chemical Industries, Ltd. Quinone derivatives, their production and use
MX9203040A (es) 1984-08-01 1992-07-31 Takeda Chemical Industries Ltd Derivados de quinona y composicion farmaceutica que los contiene.
JPS6140236A (ja) 1984-08-02 1986-02-26 Yamanouchi Pharmaceut Co Ltd ハイドロキノン誘導体
US4592867A (en) 1984-10-19 1986-06-03 Energy Conversion Devices, Inc. Synthesis method for reductant precursor
US4617317A (en) 1984-10-31 1986-10-14 Bennet Justin D Method of treating ulcerative colitis
DE3484473D1 (de) 1984-12-06 1991-05-23 Kuraray Co Chroman-verbindungen und deren herstellung.
US5229385A (en) 1986-01-30 1993-07-20 Takeda Chemical Industries, Ltd. Quinone derivatives, their production and use
US4883658A (en) 1986-04-28 1989-11-28 Holly Frank J Ophthalmic solution for treatment of dry-eye syndrome
US4804539A (en) 1986-07-28 1989-02-14 Liposome Technology, Inc. Ophthalmic liposomes
JPH0788376B2 (ja) 1986-09-02 1995-09-27 エーザイ株式会社 光学活性α−トコトリエノ−ルの製造方法
GB8626344D0 (en) 1986-11-04 1986-12-03 Zyma Sa Bicyclic compounds
US5057514A (en) 1987-02-03 1991-10-15 Suntory Limited Compounds effective as cerebral schemia treating agents
US4914088A (en) 1987-04-02 1990-04-03 Thomas Glonek Dry eye treatment solution and method
US5278151A (en) 1987-04-02 1994-01-11 Ocular Research Of Boston, Inc. Dry eye treatment solution
US5179092A (en) 1987-12-22 1993-01-12 Suntory Limited Compound effective as cerebral insufficiency improver
US5288752A (en) 1987-12-22 1994-02-22 Suntory Limited Compound effective as cerebral insufficiency improver
DK36389A (da) 1988-02-05 1989-08-06 Eastman Kodak Co Praeparat og fremgangsmaade til at forebygge vaevskader ved reperfusion
JPH01209445A (ja) 1988-02-17 1989-08-23 Fuji Photo Film Co Ltd 放射線感応性材料
JP2685785B2 (ja) 1988-03-11 1997-12-03 エーザイ株式会社 光学活性α−トコトリエノールの製造方法
AU618791B2 (en) 1988-03-16 1992-01-09 Bioindustry Development Centre Production of high concentration tocopherols and tocotrienols from palm oil by-product
DE3818696C1 (en) 1988-06-01 1989-03-30 Ems-Inventa Ag, Zuerich, Ch Process for the preparation of hydroquinone and its alkyl derivatives
US5075104A (en) 1989-03-31 1991-12-24 Alcon Laboratories, Inc. Ophthalmic carboxy vinyl polymer gel for dry eye syndrome
JPH08768B2 (ja) 1989-08-24 1996-01-10 武田薬品工業株式会社 神経成長因子分泌誘導剤
FI102273B (fi) 1989-09-11 1998-11-13 Eisai Co Ltd Kinonijohdannaiset, niiden valmistaminen ja niiden farmakologinen käyt tö
US5157132A (en) 1990-05-18 1992-10-20 Carotech Associates Integrated process for recovery of carotenoids and tocotrienols from oil
ES2084722T3 (es) 1990-05-29 1996-05-16 Boston Ocular Res Composicion para tratamiento del ojo seco.
JP3086284B2 (ja) 1991-07-05 2000-09-11 京セラミタ株式会社 電子写真感光体
ZA927277B (en) 1991-10-02 1993-05-19 Boston Ocular Res Dry eye treatment process and solution.
CA2124086A1 (en) 1991-11-22 1993-05-27 Ronald H. Lane Tocotrienols and tocotrienol-like compounds and methods for their use
EP0560568A3 (en) 1992-03-13 1994-06-29 Takeda Chemical Industries Ltd Hydroquinone derivatives and intermediates for production thereof
WO1993024650A1 (en) 1992-05-28 1993-12-09 Monash University Therapeutic compositions
CN1093360A (zh) 1992-10-02 1994-10-12 武田药品工业株式会社 2-o-烷基抗坏血酸的锂盐
US5318993A (en) 1993-04-16 1994-06-07 Bristol-Myers Squibb Company Antihyperlipidemic benzoquinones
EP0629400B1 (en) 1993-06-18 1999-09-22 Takeda Chemical Industries, Ltd. Idebenone compositions for treating Alzheimer's disease
US5600029A (en) 1994-03-09 1997-02-04 Takeda Chemical Industries, Ltd. Process for producing DL-tocopherols and intermediates therefor
CA2166722A1 (en) 1994-05-06 1995-11-16 Manoj L. Maniar Use of vitamin e tocopheryl derivatives in ophthalmic compositions
CA2196426A1 (en) 1994-08-12 1996-02-22 Shinji Terao Use of quinone and hydroquinone derivatives for the teatment of cachexia
US6150402A (en) 1994-08-15 2000-11-21 Loma Linda University Medical Center Natriuretic compounds
JPH0892151A (ja) 1994-09-29 1996-04-09 Sagami Chem Res Center アリルキノンの製造方法
US5547827A (en) 1994-12-22 1996-08-20 Eastman Kodak Company Iodochloride emulsions containing quinones having high sensitivity and low fog
EP0719552A3 (en) 1994-12-26 1997-08-20 Takeda Chemical Industries Ltd Pharmaceutical composition containing a quinone derivative or the hydroquinone thereof for the treatment of dermatitis
DK0801564T3 (da) 1994-12-28 2002-07-15 Janssen Pharmaceutica Nv Anvendelse af nebivolol som et antiatherogent middel
JP2637705B2 (ja) * 1995-03-02 1997-08-06 株式会社ナード研究所 ベンゾキノン系誘導体の製造法
US5872108A (en) 1995-03-06 1999-02-16 Interneuron Pharmaceuticals, Inc. Reduction of infarct volume using citicoline
US20030134028A1 (en) 1995-06-01 2003-07-17 Lipton, Division Of Conopco, Inc. Fat based food products
US6011046A (en) 1995-08-21 2000-01-04 Takeda Chemical Industries, Ltd. Quinone compound, its production and use as antioxidant
US6232060B1 (en) 1996-01-19 2001-05-15 Galileo Laboratories, Inc. Assay system for anti-stress agents
US5801159A (en) 1996-02-23 1998-09-01 Galileo Laboratories, Inc. Method and composition for inhibiting cellular irreversible changes due to stress
PT842165E (pt) 1996-03-25 2001-08-30 Alcon Laboratoires Inc Derivados de acido tiazolidina-4-carboxilico como agentes citoprotectores
US5894475A (en) 1996-06-28 1999-04-13 At&T Corp. Switched voice and data ATM network with billing system
AU3458997A (en) 1996-07-11 1998-02-09 Takeda Chemical Industries Ltd. Anti-beta-amyloid protein-induced cytotoxicity composition
FR2753098B1 (fr) 1996-09-06 1998-11-27 Sod Conseils Rech Applic Composition pharmaceutique comprenant au moins un inhibiteur de no synthase et au moins un piegeur des formes reactives de l'oxygene
GB9702310D0 (en) 1997-02-05 1997-03-26 Univ Hertfordshire Invention
GB9722361D0 (en) 1997-10-24 1997-12-17 Pharma Nord Uk Ltd Pharmaceutical formulation for treating liver disorders
AU746369B2 (en) 1997-11-17 2002-04-18 Lipogenics, Inc. Methods for preventing restenosis using tocotrienols
US6331532B1 (en) 1998-11-25 2001-12-18 University Of Otago Mitochondrially targeted antioxidants
BR9907278A (pt) 1998-01-29 2000-10-24 Eastman Chem Co Processos para separar um tocotrienol de uma primeira mistura de tocol, e, composição
US5969133A (en) 1998-05-22 1999-10-19 Shiongi Bioresearch Corp. Bioreductive cytotoxic agents
US6433199B1 (en) 1998-05-22 2002-08-13 Shionogi Bioresearch Corporation Quinone derivatives
CN1131217C (zh) 1998-07-31 2003-12-17 日本曹达株式会社 苯基吡咯化合物和其制备方法及抗高血脂药
US6472378B2 (en) 1998-08-31 2002-10-29 Pro-Neuron, Inc. Compositions and methods for treatment of mitochondrial diseases
IT1304406B1 (it) 1998-10-21 2001-03-19 Danital Italia S R L Preparazione per la veicolazione di principi attivi basata su acidigrassi polinsaturi del gruppo omega 3.
US6187811B1 (en) 1998-10-28 2001-02-13 Lipogenics, Inc. Methods for treating benign prostatic hyperplasia using tocotrienols
US6133322A (en) 1998-10-29 2000-10-17 Institut National De La Sante Et De La Recherche Medicale (Inserm) Quinone derivatives for treating or preventing diseases associated with iron overload
JP3258003B2 (ja) 1998-11-06 2002-02-18 富士化学工業株式会社 トコトリエノール類含有粉末、その製造方法およびそれを圧縮成型してなる錠剤
US6048891A (en) 1998-12-17 2000-04-11 Loma Linda University Medical Center Use of γ-tocopherol and its oxidative metabolite LLU-α in the treatment of natriuretic disease
JP2000202297A (ja) 1999-01-20 2000-07-25 Chemiprokasei Kaisha Ltd 新規な酸化反応用触媒およびそれを用いたｐ―ベンゾキノン類の製造方法
RU2268732C2 (ru) 1999-02-23 2006-01-27 Дзе Риджентс Оф Дзе Юниверсити Оф Калифорния Способы лечения митохондриальных нарушений
US6761903B2 (en) 1999-06-30 2004-07-13 Lipocine, Inc. Clear oil-containing pharmaceutical compositions containing a therapeutic agent
US6632443B2 (en) 2000-02-23 2003-10-14 National Research Council Of Canada Water-soluble compositions of bioactive lipophilic compounds
US6045826A (en) 1999-04-02 2000-04-04 National Research Council Of Canada Water-soluble compositions of bioactive lipophilic compounds
DE19916801A1 (de) 1999-04-14 2000-11-02 Bosch Gmbh Robert Spritzdüse für eine Scheibenwaschanlage
WO2000078296A2 (en) 1999-06-17 2000-12-28 Basf Aktiengesellschaft Tocotrienol and/or tocotrienol derivatives for the treatment or prophylaxis of glutamate- and/or calcium-induced disorders
US6395915B1 (en) 1999-09-10 2002-05-28 Technikrom, Inc. Method for producing purified tocotrienols and tocopherols using liquid chromatography
US6528042B1 (en) 1999-10-08 2003-03-04 Galileo Laboratories, Inc. Compositions of flavonoids for use as cytoprotectants and methods of making and using them
US6426362B1 (en) 1999-10-08 2002-07-30 Galileo Laboratories, Inc. Formulations of tocopherols and methods of making and using them
MY127451A (en) 1999-11-04 2006-12-29 Malaysian Palm Oil Board A method of chromatographic isolation for vitamin e isomers
US8753675B1 (en) 2000-01-20 2014-06-17 Raj K. Chopra Reduced form of Coenzyme Q in high bioavailability stable dosage forms and related applications
US6740338B1 (en) 2000-01-20 2004-05-25 Raj K. Chopra Reduced form of Cenzyme Q in high bioavailability stable oral dosage form
US6346544B2 (en) 2000-03-02 2002-02-12 Oklahoma Medical Research Foundation Desmethyl tocopherols for protecting cardiovascular tissue
WO2001092215A2 (en) 2000-06-02 2001-12-06 Us Health Superoxide-generating diazeniumdiolates, compositions comprising same, and methods for using same
DE10034233A1 (de) 2000-07-14 2002-01-24 Basf Ag Tocotrienolchinon-Cyclisierungsprodukte
US6545184B1 (en) 2000-08-15 2003-04-08 The Regents Of The University Of California Practical, cost-effective synthesis of COQ10
US20030206972A1 (en) 2000-10-13 2003-11-06 Babish John G. Compositions containing carotenoids and tocotrienols and having synergistic antioxidant effect
PL212952B1 (pl) 2000-10-26 2012-12-31 Fournier Lab Ireland Ltd Kompozycja farmaceutyczna zawierajaca fenofibrat i koenzym Q₁₀ oraz jej zastosowanie
AUPR177300A0 (en) 2000-11-29 2000-12-21 Centre For Molecular Biology And Medicine Therapeutic methods
WO2002043507A2 (en) 2000-11-30 2002-06-06 The Health Research Institute Nutrient supplements and methods for treating autism and for preventing the onset of autism
US7034054B2 (en) 2000-12-15 2006-04-25 Galileo Pharmaceuticals, Inc. Methods for the prevention and treatment of cerebral ischemia using non-alpha tocopherols
CA2430415A1 (en) 2000-12-15 2002-06-20 Galileo Laboratories, Inc. Use of tocopherol, metabolites or derivatives thereof or flavonoid metabolites or derivatives thereof in the manufacture of a medicament for the treatment of tissue ischemia
US6838104B2 (en) 2000-12-20 2005-01-04 Archer Daniels Midland Company Process for the production of tocotrienols
US20040043013A1 (en) 2000-12-28 2004-03-04 Mccleary Edward Larry Metabolic uncoupling therapy
US6300377B1 (en) 2001-02-22 2001-10-09 Raj K. Chopra Coenzyme Q products exhibiting high dissolution qualities
US6764768B2 (en) 2001-02-28 2004-07-20 Arch Development Corporation Controlled release composition
US6964969B2 (en) 2001-04-19 2005-11-15 Mccleary Edward Larry Composition and method for treating impaired or deteriorating neurological function
US6608196B2 (en) 2001-05-03 2003-08-19 Galileo Pharmaceuticals, Inc. Process for solid supported synthesis of pyruvate-derived compounds
JP2003064017A (ja) 2001-06-12 2003-03-05 Hokko Chem Ind Co Ltd オキシスチレン誘導体の蒸留方法
US7172905B2 (en) 2001-08-07 2007-02-06 The University Of Chicago Polypeptide immobilization
NZ513547A (en) 2001-08-13 2002-09-27 Antipodean Biotechnology Ltd Synthesis of triphenylphosphonium quinols (e.g. mitoquinol) and/or quinones (e.g. mitoquinone)
CA2456743A1 (en) 2001-08-21 2003-02-27 Galileo Pharmaceuticals, Inc. Tocopherol enriched compositions and amelioration of inflammatory symptoms
CA2357053A1 (en) 2001-09-04 2003-03-04 Unknown Effectiveness of a combination of antioxidant substances for the treatment of alzheimer's disease
JP2003137716A (ja) 2001-10-30 2003-05-14 Eau De Faveur:Kk 皮膚の外用剤
WO2003043570A2 (en) 2001-11-15 2003-05-30 Galileo Laboratories, Inc. Formulations and methods for treatment or amelioration of inflammatory conditions
US6667330B2 (en) 2002-01-31 2003-12-23 Galileo Pharmaceuticals, Inc. Furanone derivatives
US7078541B2 (en) 2002-02-07 2006-07-18 Galileo Pharmaceuticals, Inc. Benzofuran derivatives
US6653346B1 (en) 2002-02-07 2003-11-25 Galileo Pharmaceuticals, Inc. Cytoprotective benzofuran derivatives
GB0204232D0 (en) 2002-02-22 2002-04-10 Isis Innovation Assay
US7217133B2 (en) 2002-04-04 2007-05-15 Jeanine Thomas Method for treating pervasive development disorder
AT414082B (de) 2002-05-03 2006-09-15 Vis Vitalis Lizenz & Handels Verfahren zur herstellung von tocotrienol-angereicherten präparationen
DE60211875T2 (de) 2002-07-01 2006-10-26 Santhera Pharmaceuticals (Schweiz) Ag Screeningverfahren und Verbindungen zur Behandlung von Friedreich ataxia
AU2003287250B9 (en) 2002-10-30 2010-01-28 Ptc Therapeutics, Inc. Identifying therapeutic compounds based on their physical-chemical properties
AU2004210013A1 (en) 2003-02-10 2004-08-19 Autogen Research Pty Ltd Therapeutic molecules
CN1809384A (zh) 2003-06-25 2006-07-26 C·欧文 提高辅酶q10传送的化学组合物及方法
EP1660075A2 (en) 2003-08-08 2006-05-31 The Ohio State University Research Foundation Protective and therapeutic uses for tocotrienols
CA2536546C (en) 2003-08-22 2012-10-02 Antipodean Pharmaceuticals, Inc. Mitoquinone derivatives used as mitochondrially targeted antioxidants
US7015243B2 (en) 2003-08-28 2006-03-21 Allergan, Inc. Cyclohexyl prostaglandin analogs as EP4-receptor agonists
US7470798B2 (en) 2003-09-19 2008-12-30 Edison Pharmaceuticals, Inc. 7,8-bicycloalkyl-chroman derivatives
WO2005035491A2 (en) 2003-10-10 2005-04-21 Yasoo Health, Inc. PROCESS FOR SYNTHESIZING d-TOCOTRIENOLS FROM 2- VINYLCHROMANE COMPOUND
CA2557261A1 (en) 2004-02-23 2005-09-15 The Texas A&M University System Antioxidant compositions and methods of use thereof
US7022441B2 (en) 2004-02-25 2006-04-04 Eastman Kodak Company Silver-free black-and-white thermographic materials containing a benzoquinone and methods of imaging
JPWO2005084660A1 (ja) 2004-03-05 2007-08-09 森重 文江 ミトコンドリア病予防と対策
WO2005090602A2 (en) 2004-03-18 2005-09-29 Sucampo Ag Method for diagnosing or predicting susceptibility to optic nueropathy
US7485283B2 (en) 2004-04-28 2009-02-03 Lantheus Medical Imaging Contrast agents for myocardial perfusion imaging
WO2005115478A2 (en) 2004-05-11 2005-12-08 The Regents Of The University Of California Methods and compositions for autism spectrum disorders
DE102004032837A1 (de) 2004-07-02 2006-02-09 Beiersdorf Ag Verwendung von Wirkstoffkombinationen aus einem oder mehreren Biochinonen und einem oder mehreren Isoflavonen zur Verbesserung der Hautkonturen
DE602004022523D1 (de) 2004-07-02 2009-09-24 Novagali Pharma Sa Verwendung von Emulsionen zur intra- und periocularen Injection
US7393662B2 (en) 2004-09-03 2008-07-01 Centocor, Inc. Human EPO mimetic hinge core mimetibodies, compositions, methods and uses
GB2438544A (en) 2005-02-09 2007-11-28 Cooper Internat Corp Liquid formulations for treatment of diseases or conditions
KR101270841B1 (ko) 2005-02-28 2013-06-05 가부시키가이샤 메이지 히드로퀴논 장쇄 유도체 및／또는 페녹시 장쇄 유도체 및 이들을 함유하는 의약
ES2532997T3 (es) 2005-04-22 2015-04-06 Elizabeth Stuart Uso de tocotrienoles de vitamina E para la inhibición del patógeno intracelular obligado Chlamydia
EP2564843B1 (en) 2005-06-01 2018-12-26 Bioelectron Technology Corporation Redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers
CA2613854A1 (en) 2005-06-30 2007-01-11 Kyowa Chemical Industry Co., Ltd. Antibacterial agent composed of silver-containing aluminum sulfate hydroxide particles and use thereof
LT1933821T (lt) 2005-09-15 2020-11-10 Ptc Therapeutics, Inc. Šoninės grandinės variantai redoks aktyviųjų terapijos priemonių, skirtų mitochondrinių ligų ir kitokių būklių gydymui ir energijos biologinių žymenų moduliavimui
EP1924292A2 (en) 2005-09-16 2008-05-28 Allergan, Inc. Compositions and methods for the intraocular transport of therapeutic agents
EP1957109A2 (en) 2005-12-02 2008-08-20 Sirtris Pharmaceuticals, Inc. Modulators of cdc2-like kinases (clks) and methods of use thereof
US20070208086A1 (en) 2006-02-15 2007-09-06 The Regents Of The University Of California Ubiquinone analogs and methods of use
EP1986636B1 (en) * 2006-02-22 2013-04-24 Edison Pharmaceuticals, Inc. Phenol and 1,4-benzoquinone derivatives for use in the treatment of mitochondrial diseases
EP2000456A2 (en) 2006-03-30 2008-12-10 Idemitsu Kosan Co., Ltd. Material for organic electroluminescent device and organic electroluminescent device using the same
JP2010505958A (ja) 2006-10-10 2010-02-25 バーンハム インスティトゥート フォー メディカル リサーチ 神経防護作用組成物および方法
WO2008060949A2 (en) 2006-11-09 2008-05-22 Stc.Unm Compounds with anti-androgenic activity and the use thereof
JP2010515736A (ja) 2007-01-10 2010-05-13 エジソン ファーマシューティカルズ， インコーポレイテッド エリスロポイエチン活性またはトロンボポイエチン活性を有する化合物を用いる呼吸鎖障害の治療
GB2459809A (en) 2007-02-22 2009-11-11 Children S Hospital And Res Ct Fatty acid formulations and methods of use thereof
EP2155888B1 (en) 2007-05-24 2014-07-09 Loders Croklaan B.V. Process for producing compositions comprising tocopherols and tocotrienols
WO2008157747A1 (en) 2007-06-21 2008-12-24 The Jackson Laboratory Use of inhibition of exonuclease 1 in methods for therapy and diagnostic of neurodegenerative diseases, eye diseases, and mitochondrial disorders
US8075909B2 (en) 2007-09-04 2011-12-13 University Of Florida Research Foundation, Incorporated Contact lens based bioactive agent delivery system
DK2220030T3 (en) 2007-11-06 2016-04-11 Edison Pharmaceuticals Inc 4- (P-QUINONYL) -2-HYDROXYBUTANAMIDDERIVATER TO TREAT mitochondrial
EP2242506A4 (en) 2008-01-07 2011-12-28 Janssen Biotech Inc METHOD FOR THE TREATMENT OF ERYTHROPOIETIN HYPORESPONSE ANIMALS
EP2237664A4 (en) 2008-01-08 2013-05-22 Edison Pharmaceuticals Inc (HET) ARYL-p-CHINONE DERIVATIVES FOR THE TREATMENT OF OCHONDRIAL DISEASES
EP2262508B1 (en) * 2008-03-05 2018-10-03 BioElectron Technology Corporation SUBSTITUTED-p-QUINONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISEASES
CA2717741C (en) 2008-03-05 2018-04-03 Edison Pharmaceuticals, Inc. Treatment of hearing and balance impairments with redox-active therapeutics
US20110142834A1 (en) 2008-05-15 2011-06-16 Edison Pharmaceuticals, Inc. Treatment of hearing and balance impairments using compounds having erythropoietin activity
CA2724841A1 (en) 2008-05-22 2009-11-26 Edison Pharmaceuticals, Inc. Treatment of mitochondrial diseases with an erythropoietin mimetic
CA2729227C (en) * 2008-06-25 2018-05-22 Andrew W. Hinman 2-heterocyclylaminoalkyl-(p-quinone) derivatives for treatment of oxidative stress diseases
US20100010100A1 (en) 2008-07-09 2010-01-14 Hinman Andrew W Dermatological compositions with anti-aging and skin even-toning properties
US20100029706A1 (en) 2008-07-30 2010-02-04 Edison Parmaceuticals, Inc. a Delaware Corporation HYDROGENATED PYRIDO[4,3-b]INDOLES FOR THE TREATMENT OF OXIDATIVE STRESS
US20100029784A1 (en) 2008-07-30 2010-02-04 Hinman Andrew W Naphthoquinone compositions with anti-aging, anti-inflammatory and skin even-toning properties
MX363223B (es) 2008-09-10 2019-03-15 Bioelectron Tech Corp Tratamiento de trastornos generalizados del desarrollo con terapeuticos con actividad redox.
CN102238949A (zh) 2008-10-09 2011-11-09 拉姆斯科股份有限公司 治疗干眼综合征的组合物和方法
CA2740773A1 (en) 2008-10-14 2010-04-22 Edison Pharmaceuticals, Inc. Treatment of oxidative stress disorders including contrast nephropathy, radiation damage and disruptions in the function of red cells
ES2553557T3 (es) 2008-10-28 2015-12-10 Edison Pharmaceuticals, Inc. Proceso para la producción de alfa-tocotrienol y derivados
US20100273892A1 (en) 2009-04-28 2010-10-28 Miller Guy M Formulations of tocotrienol quinones for the treatment of ophthalmic diseases
WO2010126910A1 (en) 2009-04-28 2010-11-04 Edison Pharmaceuticals, Inc. Topical, periocular, or intraocular use of tocotrienols for the treatment of ophthalmic diseases
PL2424495T3 (pl) 2009-04-28 2018-06-29 Bioelectron Technology Corporation Leczenie dziedzicznej neuropatii nerwów wzrokowych lebera i dominującego zaniku nerwu wzrokowego chinonami tokotrienolu
LU91562B1 (en) 2009-05-04 2010-11-05 Axoglia Therapeutics S A Hydroquinone derivatives.
EA201200054A1 (ru) 2009-06-25 2012-05-30 Эмпэр Лайф Сайнсиз, Инк. Лечение токотриенолами или экстрактами, богатыми токотриенолами, первазивных расстройств развития
US9176146B2 (en) 2009-08-03 2015-11-03 Theta Biomedical Consulting & Development Co., Inc. Methods of treating autism spectrum disorders and compositions for same
US9050275B2 (en) 2009-08-03 2015-06-09 Theta Biomedical Consulting & Development Co., Inc. Methods of screening for and treating autism spectrum disorders and compositions for same
HUE037592T2 (hu) 2009-08-26 2018-09-28 Bioelectron Tech Corp Eljárások cerebrális ischemia megelõzésére és kezelésére
WO2011041452A2 (en) 2009-10-01 2011-04-07 Ampere Life Sciences, Inc. Mouse model for identifying compounds for the treatment of oxidative stress
EP2519232A1 (en) 2009-12-31 2012-11-07 Edison Pharmaceuticals, Inc. Treatment of leigh syndrome and leigh-like syndrome with tocotrienol quinones
JP2013522217A (ja) 2010-03-09 2013-06-13 エジソン ファーマシューティカルズ， インコーポレイテッド α−トコフェロールキノン誘導体の合成およびその使用方法
WO2011113018A1 (en) 2010-03-12 2011-09-15 Ampere Life Sciences, Inc. Measurement and control of biological time
EA201201374A1 (ru) 2010-04-06 2013-04-30 Эдисон Фармасьютикалз, Инк. Лечение атаксии-телеангиэктазии
AU2011245384C1 (en) 2010-04-27 2016-09-01 Bioelectron Technology Corporation Formulations of quinones for the treatment of ophthalmic diseases
WO2012009271A1 (en) 2010-07-14 2012-01-19 Penwest Pharmaceuticals Co. Methods of providing anticoagulation effects in subjects
US20130345312A1 (en) 2010-08-06 2013-12-26 Orion D. Jankowski Treatment of mitochondrial diseases with naphthoquinones
US20140031432A1 (en) 2010-08-06 2014-01-30 Ampere Life Sciences, Inc. Treatment of mitochondrial diseases with vitamin k
WO2012022467A2 (en) * 2010-08-16 2012-02-23 Santhera Pharmaceuticals (Schweiz) Ag Novel benzoquinone derivatives and use thereof as modulators of mitochondrial function
WO2012068552A1 (en) 2010-11-19 2012-05-24 Edison Pharmaceuticals, Inc. Methods for improving blood glucose control
WO2012154613A1 (en) 2011-05-06 2012-11-15 Edison Pharmaceuticals, Inc. Improved process for the preparation of d-alpha-tocotrienol from natural extracts
WO2012170773A1 (en) 2011-06-08 2012-12-13 Edison Pharmaceuticals, Inc. Adjunctive therapy for the treatment of mitochondrial disorders with quinones and naphthoquinones
US9464016B2 (en) 2011-06-14 2016-10-11 Edison Pharmaceuticals, Inc. Catechol derivatives for treatment of oxidative stress diseases
WO2013006737A1 (en) 2011-07-06 2013-01-10 Edison Pharmaceuticals, Inc. Treatment of methylmalonic aciduria, isovaleric aciduria, and other organic acidurias with tocotrienol quinones
WO2013006736A1 (en) 2011-07-06 2013-01-10 Edison Pharmaceuticals, Inc Treatment of leigh syndrome and leigh-like syndrome, including complications of sucla2 mutations, with tocotrienol quinones
JP2014520894A (ja) 2011-07-19 2014-08-25 エジソン ファーマシューティカルズ， インコーポレイテッド 非アルファトコトリエノールの存在下でのアルファトコトリエノールの選択的酸化のための方法
EP2573063A1 (en) 2011-09-23 2013-03-27 DSM IP Assets B.V. Process for preparing chiral quinone
JP6158194B2 (ja) * 2011-10-24 2017-07-05 ニコックス サイエンス アイルランド キノン系一酸化窒素供与化合物
US10806703B2 (en) 2012-01-20 2020-10-20 Lts Lohmann Therapie-System Ag Transmucosal administration system for a pharmaceutical drug
EP2620141A1 (en) 2012-01-25 2013-07-31 Santhera Pharmaceuticals (Schweiz) AG Thin film drug delivery system for the transmucosal administration of a 1,4-benzoquinone derivative
UA115789C2 (uk) 2012-09-05 2017-12-26 Трейкон Фармасутікалз, Інк. Композиція антитіла до cd105 та її застосування
EP2892516A1 (en) 2012-09-07 2015-07-15 Edison Pharmaceuticals, Inc. Quinone derivatives for use in the modulation of redox status of individuals
US9670170B2 (en) 2013-03-15 2017-06-06 Bioelectron Technology Corporation Resorufin derivatives for treatment of oxidative stress disorders
EP2970158B1 (en) 2013-03-15 2019-02-20 BioElectron Technology Corporation Alkyl-heteroaryl substituted quinone derivatives for treatment of oxidative stress disorders
US9296712B2 (en) 2013-03-15 2016-03-29 Edison Pharmaceuticals, Inc. Resorufin derivatives for treatment of oxidative stress disorders
US20140275045A1 (en) 2013-03-15 2014-09-18 Edison Pharmaceuticals, Inc. Phenazine-3-one and phenothiazine-3-one derivatives for treatment of oxidative stress disorders
WO2014138922A1 (en) 2013-03-15 2014-09-18 Indanio Bioscience Inc. Uses for idebenone and related benzoouinones in ppar-related diseases and conditions
US9868711B2 (en) 2013-03-15 2018-01-16 Bioelectron Technology Corporation Phenazine-3-one and phenothiazine-3-one derivatives for treatment of oxidative stress disorders
HK1223369A1 (zh) 2013-05-31 2017-07-28 Bioelectron Technology Corporation 用於治疗氧化应激障碍的羧酸衍生物
WO2014201155A1 (en) 2013-06-11 2014-12-18 Courtagen Life Sciences, Inc. Methods and kits for treating and classifying individuals at risk of or suffering from trap1 change-of-function
CN105873579A (zh) 2013-11-06 2016-08-17 雷普特药品公司 半胱胺及其衍生物治疗线粒体疾病的用途
WO2015183984A2 (en) 2014-05-28 2015-12-03 Stealth Peptides International, Inc. Therapeutic compositions including tocopherol and uses thereof
WO2015183963A2 (en) 2014-05-28 2015-12-03 Stealth Peptides International, Inc. Therapeutic compositions including redox-active parabenzoquinones and uses thereof
WO2016061264A1 (en) 2014-10-14 2016-04-21 The Forsyth Institute Conjugates for delivery to mitochondria
PL3233786T3 (pl) 2014-12-16 2022-06-13 Ptc Therapeutics, Inc. Polimorficzne i amorficzne postacie (r)-2-hydroksy-2-metylo-4-(2,4,5-trimetylo-3,6-dioksocykloheksa-1,4-dienylo)butanoamidu
EP3233819A1 (en) 2014-12-16 2017-10-25 Bioelectron Technology Corporation Methods for chiral resolution of trolox
JP2018502127A (ja) 2015-01-12 2018-01-25 バイオエレクトロン テクノロジー コーポレイション 放射線被曝に対する防護のためのキノン
WO2016153948A1 (en) 2015-03-20 2016-09-29 Deuterx, Llc Combination therapy using enantiopure, oxy-substituted, deuterium-enriched 5-(benzyl)-5-deutero-thiazolidine-2, 4-diones for treatment of medical disorders
US10815211B2 (en) 2015-10-08 2020-10-27 Khondrion Ip B.V. Compounds for treating mitochondrial disease
WO2017087795A1 (en) 2015-11-19 2017-05-26 Concert Pharmaceuticals, Inc. Deuterated epi-743
WO2017106803A1 (en) * 2015-12-17 2017-06-22 Bioelectron Technology Corporation Flouroalkyl, flouroalkoxy, phenoxy, heteroaryloxy, alkoxy, and amine 1,4-benzoquinone derivatives for treatment of oxidative stress disorders
WO2017123823A1 (en) 2016-01-12 2017-07-20 Bioelectron Technology Corporation Alkyl-, acyl-, urea-, and aza-uracil sulfide:quinone oxidoreductase inhibitors
WO2017180769A1 (en) 2016-04-13 2017-10-19 Capten Therapeutics Inc. Small molecules for immunogenic treatment of cancer
WO2018081644A1 (en) 2016-10-28 2018-05-03 Bioelectron Technology Corporation Methods of analyzing p-hydroquinone levels and ratios
US11013673B2 (en) 2016-11-03 2021-05-25 Repairogen Corp. Cosmetic compositions containing quinones and their topical use on skin and hair
WO2018093957A1 (en) 2016-11-15 2018-05-24 Bioelectron Technology Corporation 2-substituted amino-naphth[1,2-d]imidazol-5-one compounds or pharmaceutically acceptable salts thereof cross reference to related applications
WO2018129411A1 (en) 2017-01-06 2018-07-12 Bioelectron Technology Corporation Aryl- and heteroaryl-resorufin derivatives for treatment of oxidative stress disorders and liver and kidney disorders
WO2018191732A1 (en) 2017-04-14 2018-10-18 Bioelectron Technology Corporation Methods and compositions for treatment of inflammation and oxidative stress
BR112021007153A2 (pt) 2018-10-17 2021-07-20 Ptc Therapeutics, Inc. 2,3,5-trimetil-6-nonilcicloexa-2,5-dieno-1,4-diona para a supressão e tratamento de a-sinucleinopatias, tauopatias e outros distúrbios
WO2020252414A1 (en) 2019-06-13 2020-12-17 Ptc Therapeutics, Inc. Naphthoquinone derivatives for treatment of oxidative stress disorders
WO2021077034A1 (en) 2019-10-18 2021-04-22 Ptc Therapeutics, Inc. 2,3,5-trimethyl-6-nonylcyclohexa-2,5-diene-1,4-dione for suppressing and treating hemoglobinopathy, thalassemia, sickle cell disease and other disorders

Also Published As

Publication number Publication date
JP2019504018A (ja) 2019-02-14
US10703701B2 (en) 2020-07-07
CN108712903A (zh) 2018-10-26
AU2016369616A1 (en) 2018-07-05
CN113024369A (zh) 2021-06-25
WO2017106803A1 (en) 2017-06-22
JP2021165277A (ja) 2021-10-14
CA3008849A1 (en) 2017-06-22
EP3389646A1 (en) 2018-10-24
AU2021201605A1 (en) 2021-04-08
US20200331835A1 (en) 2020-10-22
MX2018007389A (es) 2018-08-15
US10981855B2 (en) 2021-04-20
US20210238119A1 (en) 2021-08-05
JP6905527B2 (ja) 2021-07-21
US11680034B2 (en) 2023-06-20
AU2016369616B2 (en) 2021-03-25
US20180370892A1 (en) 2018-12-27

Similar Documents

Publication Publication Date Title
MX391378B (es) Derivados de fluoroalquil-, fluoroalcoxi-, fenoxi-, heteroariloxi-, alcoxi- y amina-1,4-benzoquinona para tratamiento de trastornos de estres oxidativo.
MX2015016014A (es) Derivados de acido carboxilico para el tratamiento de trastornos por agresion oxidativa.
HK1220449A1 (zh) 治疗氧化应激障碍的试卤灵衍生物
HK1220451A1 (zh) 用於治疗氧化应激障碍的烷基-杂芳基取代醌衍生物
CY1123288T1 (el) Συνθεσεις για τροποποιηση της εκφρασης sod-1
HK1220450A1 (zh) 治疗氧化应激障碍的吩嗪-3-酮和吩噻嗪-3-酮衍生产品
CO2017011183A2 (es) Inhibidores de indolamina-2,3-dioxigenasa composiciones que los contienen y métodos de preparación
BR112019006160A2 (pt) composições e métodos para o tratamento das condições oftálmicas
UY37134A (es) Compuestos heteroarilos y composiciones que los contienen útiles como inhibidores de pad4
MX2018016273A (es) Compuestos heterociclicos como inmunomoduladores.
MX394380B (es) Compuestos dinucleótidos cíclicos para eltratamiento de cáncer
EA201790998A1 (ru) Иммуннорегуляторные агенты
BR112017002332A2 (pt) terapia de combinação para o tratamento de um paramixovírus
EA201891200A1 (ru) Композиции, содержащие бактериальные штаммы
PE20180243A1 (es) Composiciones que comprenden cepas bacterianas
MX2018008105A (es) Compuestos inhibidores de metaloenzima.
BR112017012988A2 (pt) Formas polimoráficas e amorfas de (r)-2-hidroxi-2- metil-4- (2,4,5-trimetil-3,6-dioxociclohexa-1,4-dienil) butanamida
BR112018008601A2 (pt) composições compreendendo o canabidiol e segundos agentes terapêuticos para o tratamento de câncer
MX2018011413A (es) Metodos para tratar y prevenir infeccion por c. difficile.
CL2020000085A1 (es) Moduladores de nlrp3.
BR112018000776A2 (pt) métodos para tratamento de câncer usando apilimod
IL268728A (en) Formulations of cannabinoids for the treatment of acne
NI201801172A (es) Nuevos compuestos para el tratamiento de enfermedades parasitarias
MX2017015923A (es) Inhibidores de indolamina-2,3-dioxigenasa (ido).
PE20170193A1 (es) Derivados de 6-alquinil-piridina